Boston Trust Walden Corp Acquires 236,704 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Boston Trust Walden Corp lifted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 24.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,215,624 shares of the company's stock after acquiring an additional 236,704 shares during the quarter. Boston Trust Walden Corp owned 2.56% of Amphastar Pharmaceuticals worth $35,241,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its stake in Amphastar Pharmaceuticals by 4,151.3% during the first quarter. GAMMA Investing LLC now owns 38,644 shares of the company's stock valued at $1,120,000 after purchasing an additional 37,735 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Amphastar Pharmaceuticals by 46.6% during the fourth quarter. Deutsche Bank AG now owns 34,082 shares of the company's stock valued at $1,265,000 after buying an additional 10,839 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of Amphastar Pharmaceuticals by 27.2% during the fourth quarter. ProShare Advisors LLC now owns 13,852 shares of the company's stock valued at $514,000 after buying an additional 2,958 shares during the last quarter. D.A. Davidson & CO. purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at approximately $417,000. Finally, Man Group plc purchased a new position in Amphastar Pharmaceuticals during the 4th quarter worth approximately $810,000. 65.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on AMPH. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Piper Sandler dropped their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Finally, Wells Fargo & Company cut their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $32.33.

Amphastar Pharmaceuticals Stock Up 0.5%

Shares of AMPH traded up $0.12 during midday trading on Monday, reaching $24.68. 409,007 shares of the stock were exchanged, compared to its average volume of 491,853. The firm has a 50 day simple moving average of $24.77 and a 200-day simple moving average of $29.95. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a 12-month low of $22.64 and a 12-month high of $53.96. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 8.94, a P/E/G ratio of 6.40 and a beta of 0.77.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.